Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27410441 | 1.00 | C3AR1 (0.48) | C3AR1FOLH1CTDSP1NOD1SHMT1 | |
| SCHEMBL9069283 | 0.88 | C3AR1 (0.47) | C3AR1FOLH1CTDSP1NOD1SHMT1 | |
| SCHEMBL2762953 | 0.87 | C3AR1 (0.38) | C3AR1FOLH1CTDSP1NOD1SHMT1 | |
| SCHEMBL2762951 | 0.87 | FOLH1 (0.39) | C3AR1FOLH1NOD1GGT1MEN1 | |
| SCHEMBL1263209 | 0.87 | FOLH1 (0.39) | C3AR1FOLH1NOD1GGT1MEN1 | |
| SCHEMBL61231 | 0.87 | FOLH1 (0.39) | C3AR1FOLH1NOD1GGT1MEN1 | |
| SCHEMBL143455 | 0.86 | C3AR1 (0.50) | C3AR1FOLH1CTDSP1NOD1SHMT1 | |
| SCHEMBL13993614 | 0.85 | C3AR1 (0.36) | C3AR1FOLH1CTDSP1SHMT1MEN1 | |
| SCHEMBL22702612 | 0.85 | C3AR1 (0.36) | C3AR1FOLH1CTDSP1SHMT1MEN1 | |
| SCHEMBL9185434 | 0.84 | NOD1 (0.55) | C3AR1FOLH1NOD1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-1996018405-A1 | PREVENTING CONVERSION OF CITRULLINE TO ARGININOSUCCINATE TO LIMIT PATHOLOGICAL NITRIC OXIDE OVERPRODUCTION | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0666729-A1 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009750-A1 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DARS1, CD2, FCGR2A | C3AR1 1418/4885FOLH1 282/4885CTDSP1 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.